智通财经网·2025-12-05 03:56Group 1 - The core viewpoint of the report indicates a rising trend in flu activity in China since November, suggesting a short-term focus on the flu market [1] - The report highlights a significant structural recovery trend in the pharmaceutical sector after a prolonged valuation adjustment, with continued optimism for pharmaceutical innovation and investment recovery [1] - The report notes that the positive trend in the secondary market is expected to drive a rebound in primary market financing, with ongoing favorable conditions for CXO and upstream sectors [1] Group 2 - The report states that the positive rate of flu virus among outpatient and emergency cases is approximately 45%, predominantly driven by the H3N2 strain [1] - It mentions that the ILI% reported by sentinel hospitals in southern provinces is 7.8%, higher than the previous week and above the levels of 2022 and 2024, but lower than 2023 [1] - The report provides data on the main pathogens detected in flu-like cases, with influenza virus accounting for 44.8% of the samples tested [1] Group 3 - The report discusses various antiviral drugs for flu treatment, with significant sales growth for Oseltamivir and Baloxavir during the week of November 15-21, with increases of 237% and 180% year-on-year, respectively [2] - It highlights the importance of flu vaccination as a preventive measure, with a total of 373 batches of flu vaccines approved for release since January 2025, including 230 batches of quadrivalent vaccines, a 3% increase year-on-year [2] - The report notes a decline in the approval of trivalent vaccines, with 143 batches approved, representing an 18% year-on-year decrease [2]